XML 63 R45.htm IDEA: XBRL DOCUMENT v3.25.3
COLLABORATION AND LICENSING AGREEMENTS - Narrative (Details)
$ in Thousands, ¥ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2025
JPY (¥)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues $ 110,329     $ 98,241 $ 282,105 $ 217,486  
Non-cash royalty revenue related to the sale of future royalties              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues 4,789     809 7,195 1,776  
Licensing revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues 25     20 5,065 56  
Kyowa Kirin | Non-cash royalty revenue related to the sale of future royalties              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues 3,400            
Kyowa Kirin | Kyowa Kirin Agreement | Non-cash royalty revenue related to the sale of future royalties              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues 4,789 ¥ 500.0   809 7,195 1,776  
Fosun Pharma | Fosun Agreement | Licensing revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Total revenues 0   $ 5,000 0 5,000 0  
AstraZeneca | AZ Termination Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Cost of revenue $ 0     $ 10,000 $ 12,700 $ 22,700  
Maximum potential payment per agreement             $ 75,000